Education
About Us
Working with TipRanks
Follow Us
Pharming Group (NL:PHARM)
:PHARM
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
>-0.01Last Year’s EPS
-0.02Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 13, 2025
|% Change Since: -2.51%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and successful product performance, particularly for RUCONEST and Joenja, alongside strategic expansions such as the Abliva acquisition. However, there were challenges such as an inventory impairment and potential future costs associated with Abliva, as well as regulatory hurdles for leniolisib. Despite these challenges, the company maintains a positive outlook with continued growth prospects.Company Guidance
During the Pharming Group's fourth quarter and full-year 2024 results conference call, the company provided robust guidance for 2025, projecting total revenues between $315 million and $335 million, reflecting a growth rate of 6% to 13%. The call highlighted a 21% increase in full-year 2024 revenues to $297 million, exceeding guidance, with RUCONEST sales growing by 11% to $252 million, and Joenja revenue surging by 147% to $45 million. The company also noted a strong Q4, with RUCONEST sales reaching nearly $80 million and Joenja up 65% year-over-year at $13.1 million for the quarter. Pharming plans to maintain flat operating expenses from 2024, excluding the impact of the recent Abliva acquisition, which is expected to add approximately $30 million in expenses, including $17 million in R&D costs. The acquisition is seen as a strategic move to develop a high-value pipeline, with KL1333 being a pivotal asset targeting primary mitochondrial diseases. The company's strategy focuses on expanding its portfolio, leveraging its clinical development and commercial infrastructure to achieve its vision of becoming a leading global rare disease company.Record Revenue Growth
Full-year 2024 revenues increased by 21% to $297 million, exceeding guidance range, with a strong fourth quarter and positive operating cash flow in the last two quarters.
RUCONEST Performance
RUCONEST revenue grew by 11% to $252 million, with a 9% increase in the last quarter driven by new patient enrollments and an expanded prescriber base.
Joenja Revenue Surge
Joenja revenue increased by 147% to $45 million in 2024, with significant growth seen in the US market.
Abliva Acquisition
Completion of the $66.1 million acquisition of Abliva, aimed at developing a high-value pipeline, with an anticipated $30 million in associated OpEx for 2025.
Positive Operating Profit
Second consecutive quarter of positive operating profit, attributed to higher gross profit from strong sales and active OpEx management.
---
NL:PHARM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NL:PHARM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 13, 2025 | €0.72 | €0.84 | +16.43% |
| Oct 24, 2024 | €0.84 | €0.75 | -10.69% |
| Aug 01, 2024 | €0.80 | €0.73 | -8.38% |
| May 08, 2024 | €0.90 | €0.88 | -1.79% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Pharming Group (NL:PHARM) report earnings?
Pharming Group (NL:PHARM) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is Pharming Group (NL:PHARM) earnings time?
Pharming Group (NL:PHARM) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Pharming Group stock?
The P/E ratio of Pharming Group is N/A.
What is NL:PHARM EPS forecast?
NL:PHARM EPS forecast for the fiscal quarter 2025 (Q1) is >-0.01.
---